Cernostics

About:

Cernostics is a life science company developing new molecular diagnostic tests to treat cancer.

Website: http://www.cernostics.com

Twitter/X: Cernostics

Top Investors: Ben Franklin Technology Partners of Northeastern Pennsylvania, Geisinger, Illumina Ventures, UPMC, Novitas Capital

Description:

Cernostics is a life science company developing new molecular diagnostic tests for the fight against cancer. Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple cell types, not merely tumor cells. Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics.

Total Funding Amount:

$21.3M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Danville, Pennsylvania, United States

Founded Date:

2008-01-01

Contact Email:

info(AT)cernostics.com

Founders:

Rebecca Critchley-Thorne

Number of Employees:

11-50

Last Funding Date:

2021-08-13

IPO Status:

Private

Industries:

© 2025 bioDAO.ai